trending Market Intelligence /marketintelligence/en/news-insights/trending/NKj7MTHjuN8KJtevk1VrzQ2 content esgSubNav
In This List

Altimmune garners $3.7M in US agency funding to develop anthrax vaccine

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Altimmune garners $3.7M in US agency funding to develop anthrax vaccine

Altimmune Inc. received $3.7 million in funding from the U.S. Biomedical Advanced Research and Development Authority to help advance human testing of the company's anthrax vaccine.

Altimmune said it would direct the funding to an early-stage clinical trial exploring new methods of delivering the vaccine, called NasoShield, via the nose.

The Biomedical Advanced Research and Development Authority, or BARDA, contributed $2.5 million in 2018 to the same project, which led the Gaithersburg, Md.-based company to develop the new dosing method. Previously, patients received the anthrax vaccine in a series of three injections over one month.

BARDA's contract with Altimmune allows for potential funding of $133.7 million if all options are exercised in the development process.

Anthrax is a severe illness caused by infection with bacteria naturally found in soil.